J. 4000

CALDERDALE & HUDDERSFIELD NHS FOUNDATION TRUST A. KEASKIN AUTHORISATION AND RECORD OF AGREEMENT OF NAMED HEALTH PROFESSIONALS TO SUPPLY OR ADMINISTER MEDICINES UNDER:

PATIENT GROUP DIRECTION FOR THE SUPPLY OF CLARITHROMYCIN BY REGISTERED HEALTH PROFESSIONALS IN THE EMERGENCY DEPARTMENTS



1. PGD AUTHORISATION

Position	Name	Signature	Date
Acting Clinical Director of Pharmacy	Fiona Smith	Much	22) [R
Executive Director of Nursing	Brendan Brown	Junuan M	28/03/18
Medical Director	David Birkenhead	p. Brind	28/3/18
Chairman of Medicines Management Committee	Anu Rajgopal	9	29/3/18

Date	of Patient Group Direction	: March 2018

If revision please tick box $\sqrt{\ }$

Valid Until: March 2020

Review Date: September 2019

Approved by the Trust Medicine Management Committee on: 24TH MAY 2018

PATIENT GROUP DIRECTION FOR THE SUPPLY OF CLARITHROMYCIN BY REGISTERED HEALTH PROFESSIONALS IN THE EMERGENCY DEPARTMENTS

2. CLINICAL CONDITION

Indication	Potential or established soft tissue infection, in patients allergic to penicillin. Refer to Trust antibiotic policy		
Relevant National and Local Guidelines/Information sources	Licensed use. Recognised antibiotic therapy		
Description of Patients included in treatment	AdultsChildren 1yr and over		
Description of Patients excluded from treatment under the terms of this PGD	 Children < 8kg Allergy to Erythromycin/Clarithromycin Hepatic impairment. Renal Impairment Pregnancy Patients taking any medication with which clarithromycin has a potential major inter-action Patients with a predisposition to QT interval prolongation 		
Action if patient self excludes/declines	Refer to doctor or Advanced Clinical Practitioner, consider another antibiotic		

3. TREATMENT

Name, form and strength of	Clarithromycin Tablets 500mg			
medicine	Clarithromycin Suspension 250mgs/5mls or 125mgs/5mls			
Legal Status GSL, P, POM	POM			
Dose	Adults and children over 12 years - 500mg twice daily			
	Children over 1 year (and >8kg):			
	Weight Dose			
	8-11kg 62.5mg twice daily (2.5ml 125mg/5ml)			
	12-19kg	125mg twice daily (5ml 125mg/5ml)		
	20-29 kg	187.5mg twice daily (3.75ml 250mg/5ml)		
	30-40kg 250mg twice daily (5ml 250mg/5ml)			
	41-55kg 375mg twice daily (7.5ml 250mg/5ml)			
	>56kg			
Frequency of administration	BD			
Method and route of administration	Oral			
Supporting facilities required	Resuscitation Facilities			

PATIENT GROUP DIRECTION FOR THE SUPPLY OF CLARITHROMYCIN BY REGISTERED HEALTH PROFESSIONALS IN THE EMERGENCY DEPARTMENTS

Quantity to supply/administer	Length of course Quantity Dispensed		
Duration of treatment	Adult & Child 12yrs and up – 7 days 14 tablets		
	20-40kg – 7 days 70ml (250mg/5ml)		
Detential side offerte	>41kg – 7 days 140ml (250mg/5ml)		
Potential side effects	Nausea, vomiting, diarrhoea, gastric upset, hypersensitivity		
Adada da di	reactions, hepatitis, cholestatic jaundice, cardiac-arrythmias		
Advice to patient/carer	Complete prescribed course		
	Take with or after food		
	If rash develops – stop taking		
	If jaundice develops during or after course, stop taking & consult doctor		
	Suspension – shake the bottle		
	All women of child-bearing age must be asked if they are		
	taking the oral contraceptive pill. If they are they must		
	be warned that there is a risk that Clarithromycin may		
	reduce the effectiveness of their oral contraceptive.		
	They should be advised to use an alternative method of		
	contraception whilst taking Clarithromycin and for 7 days		
	after stopping. If this coincides with the end of a pack then the next pack should be started immediately. For every day (ED) packs the placebo pills should be missed		
	out		
Managing & Reporting	All suspected adverse drug reactions occurring after		
Adverse Events	treatment following this PGD must be reported to a		
/ tavoroo Evolito	senior medical practitioner responsible for the area in		
	which the direction is in use		
	The healthcare professional administering/supplying from the BCD must also report the ADD using Trust		
	from the PGD must also report the ADR using Trust		
	incident reporting procedure		
	All serious adverse drug reactions should be reported to		
	the MHRA / CSM using the Yellow Card System. Yellow		
	cards and guidance on its use are available at the back		
Concurrent Medical	of the BNF or at www.yellowcard.gov.uk		
Concurrent Medical Conditions	Do not use if taking: - Anti-arrythmics (disopyramide),		
Conditions	anticoagulants (warfarin), anti-epileptics, reboxetine,		
	tolerodine, antivirals, anti-malarials, statins, cyclosporin,		
Fallering	theophylline. Please check BNF/BNF-C if unsure		
Follow up	Review patient by health care professional as appropriate.		
When to refer to doctor	Any reaction to medication or exacerbation of symptoms		

PATIENT GROUP DIRECTION FOR THE SUPPLY OF CLARITHROMYCIN BY REGISTERED HEALTH PROFESSIONALS IN THE EMERGENCY DEPARTMENTS

Treatment record Specify method of recording supply/administration sufficient for audit trail	 Document in electronic patient record Prescription – include name and dose of drug, volume/quantity supplied, duration of treatment Advice given - verbal or written Sign and date all documentation
---	---

4. STAFF

Professional Qualifications	Registered Nurse or Registered Paramedic	
	Current NMC or HCPC Registration	
Any Exceptions to above	Bank and Agency Staff	
Specialist competencies,	Emergency Nurse Practitioner Programme (ED) or	
qualifications and experience	Advanced Clinical Practitioner Programme (inc. Trainees) Trust PGD training	
Continuing training & education	Update in line with clinical guidelines	

5. MANAGEMENT AND MONITORING

Records to be kept for Audit Purposes	Pharmacy will retain the original signed version of the PGDs Adult – 8 years Children (under 18 years) As the requirement is until child is 25 years old or for eight years after child's death and PGDs are not child specific – this would be indefinitely (at least a minimum of 43 years) Division/Author is responsible for keeping the record/retrieval method of those authorised to work under a PGD/signature sheet to comply with the above	
Date of writing	March 2018	
Name of manager holding record of names of those authorised to work under this PGD	Louise Croxall – Matron ED CRH	

PATIENT GROUP DIRECTION FOR THE SUPPLY OF CLARITHROMYCIN BY REGISTERED HEALTH PROFESSIONALS IN THE EMERGENCY DEPARTMENTS

Names of all authors of PGD	
(to include a Dr or Dentist)	Print Name: Janet Youd
	Title: Emergency Nurse Consultant
	Signature: Jand Date: 20/3)18
	Print Name. Dr Mark Davies .
	Title: Emergency Medicine Consultant
	Signature: Date: 26/3/(7
Lead Pharmacist involved in	
preparation of PGD	Print Name: Lisa Hodgson
	Signature:
	Date: 23/3/1.8
Approval of Clinical Director	
	Print Name: Mark Davies
	Signature:
	Date:4\\$\\\\\

PATIENT GROUP DIRECTION FOR THE SUPPLY OF CLARITHROMYCIN BY REGISTERED HEALTH PROFESSIONALS IN THE EMERGENCY DEPARTMENTS

This Patient Group Direction is to be read and agreed and this Authorisation and Record of Agreement signed by all Health Professionals who will administer and/or supply treatment using it. It is the responsibility of each professional to practice only within the bounds of their own competence

A copy of the Patient Group Direction and the original, signed Record of Agreement must be held together by the Ward/Departmental Manager/Community Team Leader.

'I confirm that I have read and understood the content of this Patient Group Direction and that I am willing to work under it within my Professional Code of Practice/Conduct.'

Name of Health Professional	Designation e.g. RGN	Signature of Health Professional	Signature of Ward/Departmental/Area Manager	Date